All In Biotech

Drug Trial Radar · NCT06831344

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

A Phase 1, Open-Label, Randomized, Single-Dose, 5-Period Crossover Study to Determine the Bioavailability of Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Feb 14, 2025

Primary completion

Apr 5, 2025

Study completion Apr 10, 2025

Sponsor

Lead sponsor
Phathom Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

  • Vonoprazan ODT-1 or ODT-2 without WaterDrug

    Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water

  • Vonoprazan ODT-1 or ODT-2 with WaterDrug

    Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe

  • Vonoprazan (Reference)Drug

    Vonoprazan will be administered orally as a tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Drug Concentration (Cmax) of VonoprazanTime frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
  2. Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of VonoprazanTime frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
  3. AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of VonoprazanTime frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 7551 Metro Center Dr Ste 200

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.